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Measuring quality of life in Duchenne
muscular dystrophy: a systematic review of
the content and structural validity of
commonly used instruments
Philip A. Powell1,2* , Jill Carlton1, Helen Buckley Woods1 and Paolo Mazzone1
Abstract
Duchenne muscular dystrophy (DMD) is an inherited X-linked neuromuscular disorder. A number of questionnaires
are available to assess quality of life in DMD, but there are concerns about their validity. This systematic review
aimed to appraise critically the content and structural validity of quality of life instruments for DMD. Five databases
(EMBASE, MEDLINE, CINAHL, PsycINFO, and Cochrane Library) were searched, with supplementary searches in
Google Scholar. We included articles with evidence on the content and/or structural validity of quality of life
instruments in DMD, and/or instrument development. Evidence was evaluated against the Consensus-based
Standards for the selection of health Measurement INstruments (COSMIN) criteria. Fifty five articles featured a
questionnaire assessing quality of life in DMD. Forty instruments were extracted and 26 underwent assessment.
Forty-one articles contained evidence on content or structural validity (including 37 development papers). Most
instruments demonstrated low quality evidence and unsatisfactory or inconsistent validity in DMD, with the
majority not featuring direct validation studies in this population. Only KIDSCREEN received an adequate rating for
instrument design and a satisfactory result for content validity based on its development, yet, like the majority of
PROMs, the measure has not been directly validated for use in DMD. Further research is needed on the validity of
quality of life instruments in DMD, including content and structural validity studies in this population.
Keywords: Content validity, Duchenne muscular dystrophy, Patient reported outcome measures, Quality of life,
Structural validity
Introduction
Duchenne muscular dystrophy (DMD) is an X-linked
neuromuscular disorder with an estimated incidence of
1 in 3802–6291 live male births [1, 2]. The disease
causes progressive muscle weakness due to an absence
of the dystrophin protein, which functions to help keep
muscle cells intact. Diagnostic symptoms and functional
impairment are evident from as early as two years old
and average life expectancy of people with DMD is ap-
proximately 25 years [3], although increasingly people
with DMD are surviving into their fourth and even fifth
decades [4]. The disease progresses through four recog-
nised clinical stages characterised by increased muscle
weakness, impaired ambulation and motor functioning,
and cardiovascular and respiratory problems [5]. There
is no cure for the disease. Current clinical efforts are fo-
cused on slowing disease progression and improving the
health-related quality of life (QoL) of people with DMD,
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and health interventions are necessarily evaluated for
their cost effectiveness against this objective.
In order to attempt to measure QoL in people with
DMD a number of both generic (such as the EQ-5D [6,
7]) and condition-specific (such as the MDCHILD [8])
patient reported outcome measures (PROMs) are used.
However, concerns have been raised about the validity
of existing PROMs to comprehensively assess QoL in
DMD [9]. Given that a number of generic and
condition-specific questionnaires are available, re-
searchers and clinicians have to make a critical choice
on which measure may be most appropriate for asses-
sing QoL in people with DMD. In order to help inform
this decision, evidence-based guidance is needed on the
relative validity and psychometric performance of these
instruments. There are a number of reviews exploring
QoL and associated measures in DMD, with some pro-
viding very basic information on their psychometric
properties [9, 10]. However, no reviews to date have ap-
propriately evaluated the content validity of available
measures when it comes to assessing QoL in DMD. This
is a striking omission; content validity has been defined
by the COnsensus-based Standards for the selection of
health Measurement INstruments (COSMIN) group as
the most important property of a PROM [11–13].
Furthermore, prior reviews on QoL in neuromuscular
disorders have either not referred to, or used an out-
dated version of, COSMIN guidance. In the current
review we used up-to-date COSMIN methodology to
assess the content and structural validity of QoL
PROMs in DMD [11].
Content validity refers to the extent that the content
of a PROM adequately reflects the target construct that
is intended to be measured [14]. It can be subdivided
into the judged ‘relevance’, ‘comprehensiveness’, and
‘comprehensibility’ of a PROM, in assessing the con-
struct of interest within a target population and context
[13]. ‘Relevance’ of a PROM refers to whether the items
are relevant for the construct, target population, and
context of use of interest; the response options and re-
call period of a PROM should also be appropriate and
relevant. ‘Comprehensiveness’ is used to describe the ex-
tent to which all key aspects of the construct of interest
are covered in the PROM. Finally, ‘comprehensibility’
pertains to the understanding of the items and response
options by the population of interest [13].
A thorough assessment of a PROM’s content validity
should include studies presenting information on con-
tent validity in the population of interest, but also con-
sider the initial PROM development paper(s) (i.e.
literature describing studies on the development of the
PROM) and the content of the PROM itself [12, 13].
The consideration of development studies is important,
because the quality of how the PROM was developed
(e.g. was there a clear description of the construct to be
measured? were patients involved? etc.) necessarily has
an impact on the evaluation of the content validity of a
PROM in its subsequent use. Thus, COSMIN recom-
mends that the quality of PROM development is rated
and assessed prior to the quality of any content validity
studies [13]. Furthermore, content validity should form
the first step of the assessment of the validity of a
PROM, as it is integral to that PROM’s usefulness in
doing the job it was designed to do, and influences all
other measurement properties [15, 16]. For example, a
psychometrically responsive and internally consistent in-
strument is of little use if it is not measuring what it is
intended to measure.
COSMIN guidance states that the second most im-
portant form of the validity assessment of a PROM is
structural validity [15, 16]. Structural validity describes
the extent that scores derived from a measure ad-
equately reflect the dimensionality of the construct being
measured [17]. Quality of life is usually defined, and thus
measured, as a multidimensional construct. Therefore,
PROMs that feature multiple dimensions of QoL should
be assessed to check they accurately represent the multi-
dimensional structure of QoL in the population of inter-
est. If PROMs are designed to target a single dimension
of QoL, assessments should be undertaken to empirically
demonstrate their unidimensional nature in the target
population. If such assessments are not undertaken, sub-
sequent interpretation of the data (e.g. through generat-
ing dimensional scores) may be inaccurate. For the
purposes of this review, we define QoL as a multidimen-
sional construct involving physical (e.g., pain, fatigue),
psychological (e.g., mood, self-efficacy), and social (e.g.,
participation, stigma) components, based on the Com-
prehensive Model of QoL in Muscular Dystrophy
(CMQM) [9], and use this to define the construct of
interest. We choose to define QoL as a subjective con-
struct and do not include purely functional performance
or assessment scales that may impact on QoL. In this re-
view, we consider multi-item PROMs that assess at least
one aspect of QoL in people with DMD.
When evaluating a PROM, content and structural val-
idity can be meaningfully assessed against up-to-date
published standards by the COSMIN group, derived
from international expert consensus [12, 14]. These rat-
ings incorporate actual evidence on PROM validity and
the quality of that evidence. For example, regarding a
PROM’s ‘comprehensiveness’, a positive rating can be
given based on a content validity study if: (i) the study
quality was not rated as inadequate; (ii) patients or pro-
fessionals were interviewed; and (iii) no key concepts
were missing. For structural validity, a positive rating is
given if good model fit is observed in CFA or in IRT/
Rasch (see Methods), and can be appraised alongside a
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rating for the study’s quality. The full COSMIN stan-
dards and methodology for assessing PROMs are com-
prehensive and available in accompanying guidance
manuals [13, 16], which were adhered to when conduct-
ing the current review.
This systematic review has been designed to evaluate
the content and structural validity of QoL measures used
in people with DMD using updated COSMIN guidance
[13, 16], to provide researchers and clinicians with a ro-
bust evidence-base to help them when selecting PROMs
to measure QoL in the Duchenne population. The re-
view makes a unique contribution to the literature in be-
ing the first to assess the content validity of PROMs
used in DMD and to apply an up-to-date and thorough
COSMIN assessment of these measures. There are two
main questions being addressed:
1) Which PROMs have been used to assess QoL in
published research with boys and men diagnosed
with DMD?
2) What is the content and structural validity of these
PROMs for use in assessing QoL in boys and men
with DMD?
Methods
The review protocol was registered on PROSPERO [18].
This systematic review has been reported according to
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) checklist [19].
Search strategy and selection criteria
This review contains two searches. The first search
(Search A) was designed to identify PROMs used to
measure QoL in DMD in peer-reviewed publications.
The second search (Search B) was used to identify litera-
ture reporting on the measurement properties of these
PROMs in DMD. Search B also included the recom-
mended practice of searching for the development pa-
pers of PROMs to enable a full COSMIN assessment of
their content validity [12, 13, 15]. Full copies of the
searches are contained in Additional file 1, for
reproducibility.
Search A and selection criteria
Search A was conducted on 11th April 2018, searching
EMBASE, MEDLINE, CINAHL, PsycINFO, and the
Cochrane library, from inception. No restrictions on
date or language were applied to the search. Search A
terms are illustrated in full in Additional file 1 and in-
cluded: (I) Duchenne muscular dystrophy (and
Duchenne*) AND ((II) a search filter provided by the
PROM group at the University of Oxford to identify
PROMs (available online [20] and in Additional file 1)
OR (III) PROMs known to be used in people with DMD
based on a prior rapid review of the literature [21].
The following selection criteria were applied to the re-
sults of Search A by two independent reviewers: (I) pub-
lished in English as a full-text original research article
(i.e. not including abstracts, editorials, or reviews); (II)
used a self-reported, multi-item PROM to assess at least
one aspect of QoL in males diagnosed with DMD
(assisted or proxy-reported versions of PROMs were
considered for inclusion so long as a self-report version
of that PROM exists); and (III) in case of studies involv-
ing mixed clinical samples, at least 75% of the sample
(or subgroup), on which data from the PROM was re-
ported, was male diagnosed with DMD. The inclusion
criteria were first applied to titles and abstracts of the
hits from Search A. Records were selected for full-text
review if they matched the selection criteria, potentially
matched the criteria, or if doubt existed. Any discrep-
ancy was resolved by a third reviewer. Full text articles
were then screened for selection using the selection cri-
teria by two independent reviewers. Any disagreements
were resolved by a third reviewer through discussion. Fi-
nally, the PROMs themselves identified in the articles
were reviewed by two independent reviewers to ensure
they met the requisite inclusion criteria (i.e. assessing an
aspect of QoL).
Search B and selection criteria
Search B was conducted on 18th September 2018, with
initial searches on EMBASE, MEDLINE, CINAHL, Psy-
cINFO, and the Cochrane library, from inception. No re-
strictions on date or language were applied to the
search. Search B terms are illustrated in full in Add-
itional file 1 and included: term (I) from Search A AND
((II) PROMs identified in Search A OR term (III) from
Search A) AND (IV) a search filter1 by the COSMIN
group for identifying studies on measurement properties
[22] (available online [23] and in Additional file 1). Over
and above that of Search A, the following additional se-
lection criteria was applied to the results of Search B:
(IV) described data on the content and/or structural val-
idity of the PROMs identified in Search A in males diag-
nosed with DMD; (V) included a PROM validated in
English, with a free/review copy available to access.
As recommended in the COSMIN approach [15], fol-
low up searches were conducted on Google Scholar to
identify key development papers for the PROMs identi-
fied in Search A and taken forward for review (see Sec-
tion 3.2). Google Scholar was searched (last searched
1A less-restrictive and simplified version of this filter was applied to
the Cochrane Library and CINAHL searches, due to a low number of
hits prior to filtering for the measurement properties (see Add-
itional file 1 for full search strategies).
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14th November 2018) with the names and acronyms of
the PROMs (version numbers omitted) and the first 100
hits were screened for inclusion [15]. Search results were
initially screened by title, with any relevant and poten-
tially relevant papers exported to a database. Following
the removal of duplicates against the primary searches,
records were screened by abstract and then full text
against selection criteria. As per COSMIN guidance, de-
velopment papers for the PROMs were not subject to
any of the inclusion criteria noted above and were in-
cluded in any published form [13, 15]. Results of the
searches were screened for inclusion by two reviewers.
Finally, citation tracking of all eligible articles identi-
fied in Search B was conducted by reviewing references
and citations on Google Scholar (last searched 6th
February 2019) for any articles not identified in the ini-
tial searches that may meet the inclusion criteria. All ref-
erences and citations were reviewed, except where
citations became unmanageable (i.e. > 500 citations),
when “Duchenne” was searched for within the citing ar-
ticles to filter the hits for manageable review. Search re-
sults were initially screened by title, with any relevant
and potentially relevant papers exported to a database.
Following the removal of duplicates against the primary
searches, records were screened by abstract and then full
text against selection criteria. Results of the searches
were screened for inclusion by two reviewers.
Data extraction and COSMIN risk of bias assessment
Data extraction was undertaken by two reviewers using
a pre-prepared data extraction sheet, with consensus on
any ambiguities reached through discussion. The data
extraction sheet was informed by the tools developed by
COSMIN on reporting guidance [16], and included
study characteristics (authors, year, journal, country, lan-
guage, study type); details of the PROM used (name,
mode of administration, recall period, total N subdo-
mains, subdomain names, total and subdomain N items,
total and subdomain response levels, total and subdo-
main score ranges); DMD sample characteristics if ap-
plicable (N, age, percentage ambulatory, total and
subdomain PROM score, total and subdomain observed
ranges); details of PROM development if applicable
(construct definition, target population, original lan-
guage, intended context of use, patient involvement);
details of content validity results if applicable (sum-
marised results, e.g. findings from a cognitive debriefing
exercise); and details of structural validity results if ap-
plicable (analytic model, summarised results, e.g. fit sta-
tistics, tests of model assumptions for IRT/Rasch).
The methodological quality of the PROM development
papers, and studies on content and structural validity
were assessed (at the study level) using up-to-date COS-
MIN standards via the new COSMIN risk of bias
checklist [24]. A total rating for relevance, comprehen-
siveness, and comprehensibility (content validity aspects)
of a PROM is determined separately, alongside a total
rating for the methodological quality of a structural val-
idity study [24]. When rating the methodological quality
of the studies, each COSMIN standard (or item) is
ranked on a 4-point scale: “very good”, “adequate”,
“doubtful”, and “inadequate”. Total ratings are deter-
mined using the lowest rating for any item for that study
(i.e. worst score counts) [25]. Studies were initially rated
independently by two reviewers, and, in the case of di-
vergence, consensus was reached in a subsequent face-
to-face meeting. This information on risk of bias is used
to inform quality of evidence (see section 2.2).
Assessment of measurement properties
In order to synthesise and assess evidence on content
validity, two reviewers independently rated the results of
PROM development studies, content validity studies,
and the content of the PROM itself on 10 COSMIN cri-
teria [13], agreed upon by international consensus [12].
These criteria included: whether the included items were
relevant for (I) the construct of interest, (II) the popula-
tion of interest, and (III) the context of use of interest;
whether the (IV) response options and (V) recall period
were appropriate; whether (VI) all key concepts were in-
cluded; whether (VII) the PROM instructions and (VIII)
PROM items and response options were understood by
the population of interest as intended; whether (IX) the
PROM items were appropriately worded; and whether
(X) the response options matched the question. Ratings
for each source of evidence were made separately, using
COSMIN guidance [13] (p.54) and could either be posi-
tive (+), negative (−), or indeterminate (?). Reviewers’
ratings were made based on the judgement of the re-
searchers, who have experience in PROM design and
work with people with DMD, including direct qualitative
research [26, 27]. When reviewers considered whether
the items were relevant or comprehensive for the con-
struct of interest, they were compared against the
CMQM [9]. Accordingly, a PROM would be sufficiently
comprehensive (+) if it included items covering physical,
psychological, and social aspects of QoL. When judging
the appropriateness of the recall period, reviewers con-
sidered any defined recall period of up to 4 weeks as ap-
propriate (+), as children aged 8 years and above can
recall up to this length of time with sufficient accuracy
[28]. When rating the appropriateness of response op-
tions, bearing in mind the target sample (i.e. a child or
adult PROM), reviewers took into account the numerical
range, how the response options were visually displayed,
and the perceived cognitive complexity of the options
(including wordiness, degree of variation throughout the
questionnaire, and the use of reversed ordering).
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Following the above assessment, an overall (qualita-
tively synthesised) judgment on the relevance, compre-
hensiveness, and comprehensibility of each PROM was
made, which could be sufficient (+), insufficient (−), or
inconsistent (±), using COSMIN guidance [13] (p.58).
For example, if all sources of evidence were rated posi-
tive (+) for relevance, then the overall rating for the
PROM would be sufficient (+). As recommended by
COSMIN [13], more weight was given to content valid-
ity studies, then development studies, then ratings of the
PROM by reviewers. Ratings were compared and com-
bined across the two reviewers by consensus. As per
COSMIN guidance [13], only available evidence was
taken into account when assessing content validity, so,
for example, if there were no content validity studies in
DMD available for that PROM, assessment was made
based on the ratings of any PROM development studies
and the ratings of reviewers. The fact that the PROM
had no content validation studies in DMD is then
reflected in a lower quality of evidence rating (see
below). An example content validity rating spreadsheet
for the KIDSCREEN-52, including the rules for
synthesising the individual ratings is included in
Additional file 2.
Evidence on structural validity was assessed against
the updated COSMIN criteria for good measurement
properties, using the same rating scale as above [16].
Specifically, a positive (+) rating would be given for a
CFA featuring a CFI, TLI or comparable measure > 0.95
OR RMESA < 0.06 OR SRMR < 0.08. For an IRT/Rasch
model, a positive (+) rating would be given for no viola-
tion of unidimensionally (e.g. assessed with the fit statis-
tics above) AND no violation of local independence (e.g.
residual correlations among items after controlling for
the dominant factor < 0.20) AND no violation of mono-
tonicity (e.g. evidenced graphically or item scalability >
0.30) AND adequate model fit (e.g. χ2 < 0.01, infit/outfit
mean squares ≥0.5 and ≤ 1.5 OR Z-standardized values >
− 2 and < 2. A negative (−) rating would be given if these
criteria were not met in the data and an indeterminate
(?) rating would be given if model fit was not reported.
Finally, the quality of the evidence was graded using a
modified GRADE approach [29], as either “high”, “mod-
erate”, “low”, or “very low”. The GRADE approach takes
into account the risk of bias of studies (or study quality);
(in) consistency across studies; imprecision (based on
sample sizes); and indirectness (of evidence) [16]. The
evidence is assumed to be high, then is downgraded by
1–3 points based on the degree of risk of bias (including
quality and absence of content validity studies), 1–2
points based on inconsistency, and 1–2 points based on
indirectness. Further details on how to apply all of the
above criteria are provided elsewhere in comprehensive
manuals, which were followed when conducting this
review [13, 16]. The quality of this systematic review it-
self was appraised against a recently developed COSMIN
checklist to assess the quality of systematic reviews of
health-related PROMs [22].
Results
Results of search A – PROMs used to measure quality of
life in DMD
After removing duplicates, 1733 records were identified
through database searching for Search A. Of these, 1521
were excluded at the title/abstract review stage, leaving
212 papers for full-text review. Of these 212 papers, 84
were excluded as they were not full-text published re-
search articles; 25 did not meet the required sample cri-
teria of at least 75% of the sample being boys or men
with DMD; 21 were judged not to be assessing QoL; 16
were not published in English; and finally 11 papers did
not feature a multi-item PROM. Five articles were add-
itionally excluded during the review of the actual PROM
used in the manuscript for not assessing QoL. Accord-
ingly, a total of 50 records from the initial searches met
the selection criteria for Search A. A further 5 articles
that met the selection criteria for Search A were added
as a result of citation tracking, giving a total of 55
records.
Table 1 summarises the PROMs used to assess QoL in
DMD from the full-texts meeting the selection criteria at
Stage 1 (n = 55). A total of 40 PROMs used to assess at
least one aspect of QoL in DMD were identified in pub-
lished research articles through database searching (the
two HUI classification systems use the same 15-item
PROM). The majority of the PROMs were multidimen-
sional (n = 32), designed to assess a range of different
facets of QoL. The remaining unidimensional scales
were designed to assess: activity limitations (CALI);
anxiety (GAD-7); depression (BDI, DIKJ, PHQ-9); fatigue
severity (FSS); life satisfaction (SWLS); or quality of life/
health-related quality of life unidimensionally (KIDS
CREEN, SOLE). Twenty-four of the PROMs had ver-
sions designed for completion by adult or young adult
respondents, and 26 had versions designed for children.
The most popular PROMs used in published research
articles assessing QoL in people with DMD were the
PedsQL 4.0 GCS (18 articles); PedsQL 3.0 NMM (10 ar-
ticles); and the SF-36 (8 articles).
Results of search B – evidence on measurement
properties of PROMs
After removing duplicates, 92 records were identified
through database searching for Search B. Of these, 51
had already been excluded during Search A. Eighteen
unique records were found, 14 were excluded at title/ab-
stract review stage, leaving 4 papers for full-text review.
Of these 4 papers, 3 were excluded because they were
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Table 1 Patient reported outcome measures assessing quality of life identified in published articles with samples of people with DMD
PROM Respondent
type
Recall Period N dimensions
(items)
Dimensions of quality of life
assessed
Response options Total score range Origin Validated English
copy and
development
papers freely
available for
review?
36-item Short-Form Health Survey
(SF-36) v1.0 [30–37]
Adult self-
report
Varies by
dimension
8 + a single item
of perceived
change in health
(36 items)
Physical functioning; bodily
pain; role limitations due to
physical health problems;
role limitations due to
personal or emotional
problems; emotional well-
being; social functioning;
energy/fatigue; general
health perceptions
Varies by
dimension
No total score
calculated
USA Yes
SF-36 Health Survey v2.0 [38] Adult self-
report
Varies by
dimension
8 + a single item
of perceived
change in health
(36 items)
Assumed same as SF-36 v1.0 Varies by
dimension
No total score
calculated
USA No
Autoquestionnaire Qualité de vie
Enfant Imagé (AUQEI) [39]
Child self-
report
Unknown/
undefined
4 + a total score
(26 items)
Autonomy; leisure;
functioning; family; total
0–3 rating scale
(with pictures)
0–78 (raw) France No
Beck Depression Inventory I (BDI) [34] Adult
interview or
self-report
Present/today 1 total score (21
items)
Depression 0–3 rating scale 0–63 (raw) USA Yes
Behavior Assessment System for
Children (BASC) first edition [40]
Child self-
report
Parent
report
Teacher
report
Unknown
(withdrawn from
use, superseded
by BASC-II and
BASC-III)
Unknown
(withdrawn from
use, superseded
by BASC-II and
BASC-III)
Unknown (withdrawn from
use, superseded by BASC-II
and BASC-III)
Unknown
(withdrawn from
use, superseded
by BASC-II and
BASC-III)
Unknown
(withdrawn from
use, superseded
by BASC-II and
BASC-III)
USA No
Child Activity Limitations Interview
(CALI) [40]
Child
interview or
self-report
Last 4 weeks 1 total score (8
items chosen
from a set of 21)
Activity limitations 0–4 rating scale 0–32 (raw) USA Yes
Child Health Questionnaire - Parent
Form 50 (CHQ-PF50) [41, 42]
Parent self-
report
Last 4 weeks (past
year for change in
health)
14 (50 items) Physical functioning; role/
social limitations – physical;
role/social limitations –
emotional; role/social
limitations – behavioral;
general health perceptions;
bodily pain/discomfort; family
activities; parent impact –
time; parent impact –
emotion; self-esteem; mental
health; behaviour; family
cohesion; change in health
Varies by
dimension
No total score
calculated
USA No
P
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Table 1 Patient reported outcome measures assessing quality of life identified in published articles with samples of people with DMD (Continued)
PROM Respondent
type
Recall Period N dimensions
(items)
Dimensions of quality of life
assessed
Response options Total score range Origin Validated English
copy and
development
papers freely
available for
review?
Children’s Assessment of Participation
and Enjoyment (CAPE) [43–45]
Child and
young
adults self-
report or
interview
Unknown/
undefined
5 + a total score
(55 items)
Diversity of activities; intensity
of activities (frequency of
participation); enjoyment of
activities; with whom; where;
total participation
Varies by
dimension
0–55 (raw) USA No
Depressions-Inventar für Kinder und
Jugendliche (DIKJ) 2nd edition [34]
Child self-
report
Unknown/
undefined
1 total score (26
items)
Depression Unknown/
undefined
0–46 (raw) Germany No
DISABKIDS generic module
(DCGM-37) [34]
Child self-
report
Proxy report
Past 4 weeks 6 + a total score
(37 items)
Independence; emotion;
social inclusion; social
exclusion; limitation;
treatment; total
1–4 rating scale 37–148 (raw) Multi-
country
Yes
DISABKIDS – Smileys [34] Child self-
report
Proxy report
Assumed same as
DCGM-37
Assumed same as
DCGM-37 (12
items)
Assumed same as DCGM-37 Assumed same as
DCGM-37 (with
pictures)
12–48 (raw) Multi-
country
No
Dutch Children AZL/TNO
Questionnaire Quality of Life Short
Form (DUC-25) [45]
Child self-
report
Unknown/
undefined
4 + a total score
(25 items)
Physical; emotional; social;
home functioning; total
0–4 rating scale 0–100 (raw) Netherlands No
EuroQoL 5-domain 3-Level
(EQ-5D-3L) [46, 47]
Adult self-
report
Proxy report
Present/today 5 (5 items) + self-
rated health VAS
Mobility; self-care; usual
activities; pain/discomfort;
anxiety/depression
1–3 rating scale −0.594 – 1 (utility
scores)
Multi-
country
Yes
Fatigue Severity Scale (FSS) [36] Adult self-
report
Within last week 1 total score (9
items) + global
fatigue VAS
Fatigue severity 1–7 rating scale 1–63 (raw) USA Yes
Generalized Anxiety Disorder Scale
7-item (GAD-7) [48]
Adult self-
report
2 weeks 1 total score (7
items)
Anxiety 0–3 rating scale 0–21 (raw) USA Yes
Health Utilities Index Questionnaire
mark 2 (HUI-2) 15Q [49, 50]
Child self-
report
Adult self-
report
Proxy report
During past 4
weeks
7 (15 items) Sensation; mobility; emotion;
cognition; self-care; pain;
fertility
Varies by
dimension
−0.03 – 1
(utility scores)
Canada Yes
Health Utilities Index Questionnaire
mark 3 (HUI-3) 15Q [49, 50]
Child self-
report
Adult self-
report
Proxy report
During past 4
weeks
8 (15 items) Vision; hearing; speech;
ambulation; dexterity;
emotion; cognition; pain
Varies by
dimension
−0.36 – 1
(utility scores)
Canada Yes
Hospital Anxiety and Depression
Scale (HADS) [36, 47]
Adult self-
report
Last week 2 (14 items) Anxiety; depression 0–3 rating scale No total score
calculated
UK Yes
Individualized Neuromuscular Quality
of Life Questionnaire (INQOL) [38]
Adult self-
report
At the moment 10 + a total score
(45 items)
Weakness; locking; pain;
fatigue; activities;
7-point rating
scale, varies by
Scoring unclear UK Yes
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Table 1 Patient reported outcome measures assessing quality of life identified in published articles with samples of people with DMD (Continued)
PROM Respondent
type
Recall Period N dimensions
(items)
Dimensions of quality of life
assessed
Response options Total score range Origin Validated English
copy and
development
papers freely
available for
review?
independence; social
relationships; emotions; body
image; treatment; total
dimension
KIDSCREEN-10 [51] Child self-
report
Proxy report
Last week 1 total score (10
items)
Health-related quality of life 1–5 rating scale 10–50 (raw) Multi-
country
Yes
KIDSCREEN-27 [52] Child self-
report
Proxy report
Last week 5 (27 items) Physical well-being;
psychological well-being;
autonomy and parent relation;
social support and peers;
school environment
1–5 rating scale No total score
calculated
Multi-
country
Yes
KIDSCREEN-52 [53] Child self-
report
Proxy report
Last week 10 (52 items) Physical well-being;
psychological well-being;
moods and emotions; self-
perception; autonomy;
parent relation and home life;
financial resources; social
support and peers; school
environment; social
acceptance (bullying)
1–5 rating scale No total score
calculated
Multi-
country
Yes
Life Satisfaction Index for Adolescents
(LSIA) [54–57]
Child and
young
adults self-
report
At present 5 + a total score
(45 items)
General well-being;
interpersonal relationships;
personal development;
personal fulfilment; leisure
and recreation; total
1–5 rating scale
(plus 0 = N/A)
0–225 (raw) Canada Yes
Muscular Dystrophy Child Health
Index of Life with Disabilities
(MDCHILD) [8]
Child self-
report
Past 4 weeks 7 + a total score
(47 items)
Activities of daily living &
independence; positioning,
transferring, & mobility;
comfort & endurance;
emotions & behaviour; social
interaction & school; health;
your overall quality of life; total
Varies by
dimension
0–100
(transformed)
Canada Yes
Neurological Disorders Quality of Life
Questionnaire (Neuro-QoL) [35]
Adult self-
report
Varies by
dimension
Up to 16 (up to
564 items in item
banks)
Ability to participate in social
roles and activities; anxiety;
bowel function; cognitive
function; communication;
depression; emotional and
behavioral dyscontrol; fatigue;
lower extremity function –
mobility; positive affect and
well-being; satisfaction with
social roles and activities;
1–5 rating scale No total score
calculated
USA Yes
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Table 1 Patient reported outcome measures assessing quality of life identified in published articles with samples of people with DMD (Continued)
PROM Respondent
type
Recall Period N dimensions
(items)
Dimensions of quality of life
assessed
Response options Total score range Origin Validated English
copy and
development
papers freely
available for
review?
sleep disturbance; sexual
function; stigma; upper
extremity function – fine
motor, ADL; urinary/bladder
function
Offer Self-Image Questionnaire for
Adolescents (OSIQ) [54, 57]
Child and
young adult
self-report
or interview
Unknown/
undefined
11 + a total score
(130 items)
Impulse control; emotional
tone; body and self-image;
social relationships; morals;
vocational and educational
goals; family relationships;
mastery of the external world;
psychopathology; superior
adjustment; total
1–6 rating scale 130–780 (raw) USA No
Patient Health Questionnaire 9-item
(PHQ-9) [48]
Adult self-
report
2 weeks 1 total score (9
items)
Depression 0–3 rating scale 0–27 (raw) USA Yes
Pediatric Neurological Disorders
Quality of Life Questionnaire
(Pediatric Neuro-QoL) [35]
Child self-
report
Varies by
dimension
Up to 11 (up to
161 items in item
banks)
Anger; anxiety; cognitive
function; depression; fatigue;
lower extremity – mobility;
pain; social relations –
interaction with adults; social
relations – interaction with
peers; stigma; upper extremity
– fine motor, ADL
1–5 rating scale No total score
calculated
USA Yes
Pediatric Outcomes Data Collection
Instrument (PODCI) [58–61]
Child self-
report
Proxy report
Varies by
dimension
7 (86 items) Global function & comfort;
upper extremity function;
physical function and sport;
transfers and mobility;
comfort; POSNA happy and
satisfied; POSNA expectations
Varies by
dimension
No total score
calculated
USA Yes
Pediatric Quality of Life Inventory
(PedsQL) 3.0 DMD module [62, 63]
Child and
young adult
self-report
Proxy report
Past month or
past 7 days (acute
version)
4 (18 items) Daily activities; treatment
barriers; worry; communication
0–4 rating scale No total score
calculated
USA Yes
PedsQL 3.0 Multidimensional fatigue
scale (MFS) [63, 64]
Adult self-
report
Child and
young adult
self-report
Proxy report
Past month or
past 7 days (acute
version)
3 + a total score
(18 items)
General fatigue; sleep/rest
fatigue; cognitive fatigue;
total fatigue
0–4 rating scale 0–100
(transformed)
USA Yes
PedsQL 3.0 Neuromuscular module
(NMM) [35, 50, 51, 63–69]
Child and
young adult
self-report
Past month or
past 7 days (acute
version)
3 + a total score
(25 items)
About my/my child’s
neuromuscular disease;
communication; about our
0–4 rating scale 0–100
(transformed)
USA Yes
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Table 1 Patient reported outcome measures assessing quality of life identified in published articles with samples of people with DMD (Continued)
PROM Respondent
type
Recall Period N dimensions
(items)
Dimensions of quality of life
assessed
Response options Total score range Origin Validated English
copy and
development
papers freely
available for
review?
Proxy report family resources; total
Pediatric Quality of Life Inventory
(PedsQL) 4.0 Generic Core Scales
(GCS) [35, 43, 51, 58, 61–65, 67, 70–77
]
Adult self-
report
Child and
young adult
self-report
Proxy report
Past month or
past 7 days (acute
version)
5 + a total score
(23 items)
Physical health; psychosocial
health; emotional functioning;
social functioning; school
functioning; total
0–4 rating scale 0–100
(transformed)
USA Yes
PedsQL 4.0 Generic Short-form
(SF-15) [78]
Adult self-
report
Child and
young adult
self-report
Proxy report
Past month or
past 7 days (acute
version)
5 + a total score
(15 items)
Physical health; psychosocial
health; emotional functioning;
social functioning; school
functioning; total
0–4 rating scale 0–100
(transformed)
USA Yes
Pittsburgh Sleep Quality Index
(PSQI) [35, 74]
Adult self-
report
Past month 8 + a total score
(10 items)
Subjective sleep quality; sleep
latency; sleep duration; sleep
efficiency; sleep disturbance;
use of sleep medication;
daytime dysfunction; total
Varies by
dimension
0–21 (raw) USA Yes
Satisfaction with Life Scale
(SWLS) [48, 54]
Adult self-
report
Undefined/
present time
1 total score (5
items)
Life satisfaction 1–7 rating scale 5–35 (raw) USA Yes
Strength and Difficulties
Questionnaire (SDQ) [79–81]
Child self-
report
Proxy report
Last 6 months 5 + a total score
(25 items) + an
impact
supplement
Emotional symptoms;
conduct problems;
hyperactivity/inattention;
peer relationship problems;
total difficulties; prosocial
behaviour
0–2 rating scale 0–40 (raw) UK Yes
Strips of Life with Emoticons
Questionnaire (SOLE) [82]
Child self-
report
Specific scenarios 1 total score (33
items)
Quality of life 0–2 rating scale
(with pictures)
0–66 (raw) Italy No
TNO-AZL Children’s Quality of Life
questionnaire (TACQoL) [83]
Child self-
report
Proxy report
The last few
weeks
7 (56 items) Physical functioning; motor
functioning; independent
daily functioning; cognitive
functioning and school
performance; social contacts;
positive moods; negative
moods
Varies by
dimension
No total score
calculated
Netherlands No
TNO-AZL
Adult Quality of Life
questionnaire (TAAQoL) [83]
Adult self-
report
In the last month 12 (45 items) Gross motor functioning; fine
motor functioning; cognition;
sleep; pain; social contacts;
daily activities; sex; vitality;
happiness; depressive mood;
anger
Varies by
dimension
No total score
calculated
Netherlands No
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Table 1 Patient reported outcome measures assessing quality of life identified in published articles with samples of people with DMD (Continued)
PROM Respondent
type
Recall Period N dimensions
(items)
Dimensions of quality of life
assessed
Response options Total score range Origin Validated English
copy and
development
papers freely
available for
review?
World Health Organisation Quality
of Life Scale-Brief Version
(WHOQOL-BREF) [33, 35–37]
Adult self-
report or
interview
Proxy report
2 weeks 4 (26 items, 24
items make up
domain scores)
Physical health; psychological;
social relationships; environment
1–5 rating scale No total score
calculated
Multi-
country
Yes
References next to PROM names represent published studies where the PROM has been used in a sample of people with DMD. PROM = patient reported outcome measure
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not full-text primary research articles; and 1 did not
meet the sample selection criteria. Of the remaining 23
records that had already met the selection criteria for
Search A, 11 were excluded at full-text for containing in-
formation on measurement properties other than, and
not including, content and structural validity; 4 were ex-
cluded as not containing information on measurement
properties; and 3 for including a PROM that did not
have a validated English copy that was free and/or avail-
able for review. The remaining 5 papers that met the se-
lection criteria for Search B featured evidence on
content validity (n = 3, of which one was classified as a
development paper) and structural validity (n = 2). Fi-
nally, 33 PROM development papers were identified
through a review of Google Scholar search results and 3
PROM development papers were identified through cit-
ation tracking, resulting in a final selection of 41 papers
that met the selection criteria for Search B (see Fig. 1).
These included 37 development papers, 2 content valid-
ity studies in DMD, and 2 structural validity studies in
DMD.
The observed proportionate agreement between re-
viewers during selection, based on the primary database
searches, was 92.4% at title/abstract, with Cohen’s κ =
0.51 or “moderate agreement” and is similar to other
published reviews [84, 85]. At full-text review, the ob-
served proportionate agreement was 93.5% with Cohen’s
κ = 0.82 or “almost perfect agreement”.
Following the searches, 26 PROMs were taken forward
for COSMIN quality assessment on content and struc-
tural validity in DMD (Table 2). The remaining 14
PROMs were not assessed for the following reasons: a
copy of the PROM itself and/or necessary development
papers were not freely accessible for review (CAPE,
CHQ-PF50, DISABKIDS Smileys, OSIQ, SF-36 v2); no
formally validated English copy of the PROM was avail-
able or in use (AUQEI, DIKJ, DUC-25, SOLE, TAAQoL,
TACQoL); the PROM was no longer available or recom-
mended for use (BASC 1st edition, which has been su-
perseded by the BASC 2); or it was unclear from the
study which of a large number of possible variants of a
PROM were used (pediatric Neuro-QoL, Neuro-QoL).
Content validity – appraisal of PROM development
studies
Table 2 summarises key characteristics and COSMIN
quality assessment of the development of the PROMs in-
cluded in the review. Five PROMs were developed to be
intended for use specifically within neuromuscular disor-
ders (INQoL, PedsQL 3.0 NMM) or DMD (LSIA,
MDCHILD, PedsQL 3.0 DMD module). Eleven PROMs
either had no patients involved in their development, or
it was unclear if patients were involved.
The joint most common COSMIN quality rating
assigned to the PROMs for concept elicitation was inad-
equate (n = 12). This was primarily due to: the PROM
development study not being performed in a sample of
patients representing the target population (BDI, EQ-
5D-3L, GAD-7, HADS, HUI 15Q, PedsQL 3.0 MFS,
PHQ-9, SDQ, SF-36, and SWLS); or inadequacies within
the details of the qualitative methods used (FSS, INQoL).
The concept elicitation study of 11 further PROMs was
rated as doubtful due to at least some unclear details/
suspected problems within the qualitative methods used
(CALI, DCGM-37, LSIA, MDCHILD, PODCI, PedsQL
3.0 NMM, PedsQL 3.0 DMD, PedsQL 4.0 GCS, PedsQL
4.0 SF-15, PSQI, WHOQOL-BREF). Only the KIDS
CREEN family of measures (n = 3) received an adequate
rating for concept elicitation and PROM design. How-
ever, the KIDSCREEN measures received a doubtful rat-
ing for the overall PROM development study, for failing
to provide evidence that comprehensibility and compre-
hensiveness were assessed in the cognitive interview/
pilot study of the PROM.
Content validity – appraisal of content validity studies
Only 2 published articles had independently assessed the
content validity of the QoL PROMs in samples of people
with DMD (Table 3). Neither of these studies were con-
ducted in an English language context, and instead were
cross-cultural validation studies. Hu et al. (2013) [67]
assessed the relevance, comprehensiveness, and compre-
hensibility of the PedsQL 3.0 NMM in Chinese children
with DMD. Simon et al. (2017) [56] assessed compre-
hensibility of the LSIA in Brazilian children with DMD,
and comprehensiveness in professionals. However, both
of these studies received ratings of doubtful due to at
least some unclear details/suspected problems within the
qualitative methods used.
Content validity evidence synthesis
The evidence from the PROM development papers and
content validity studies was combined with reviewer rat-
ings of the PROMs to produce a synthesis of the avail-
able evidence using the 10 COSMIN criteria for good
content validity [13]. Most of the quality of the evidence
was downgraded from High to Low or Very Low due to
the assessment being based on development studies of
doubtful or inadequate quality, respectively [13]. Only
the LSIA and the PedsQL 3.0 NMM had moderate sup-
porting evidence, featuring independent content validity
studies as well as development papers. The KIDSCREEN
measures and the LSIA were the only PROMs to receive
satisfactory results for all three dimensions of content
validity: relevance; comprehensiveness; and comprehen-
sibility, based on the evidence available. Full synthesised
results are presented in Table 4.
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Structural validity - appraisal of structural validity studies
Two studies had assessed the structural validity of the
PROMs included in this review in samples of people
with DMD (Table 5). Both of these were conducted
using English versions of the PROMs and either in the
UK or USA. Lim et al. (2014) [72] assessed the structural
validity of the PedsQL 4.0 GCS using an unspecified
Rasch model in 63 boys with DMD. This study received
a COSMIN quality rating of doubtful because it was
doubtful that the sample size included in the analysis
was adequate. Landfeldt et al. (2018) [66] assessed the
structural validity of the PedsQL 3.0 NMM using a
Rasch partial-credit model (PCM) in 278 people with
DMD. This study received a very good COSMIN quality
rating for its methodological content.
Structural validity evidence synthesis
Of the 2 studies that assessed the structural validity of
the PedsQL 4.0 GCS and PedsQL 3.0 NMM in people
with DMD, neither provided satisfactory results (Table
4). First, the structural validity of the PedsQL 4.0 GCS in
people with DMD received an indeterminate rating, as
key details of the results from the Rasch model denoting
good measurement properties were not reported. Due to
the risk of bias assessment of Lim et al. (2014) [72] the
quality of the evidence supporting this indeterminate
Fig. 1 Flow diagram of search strategy and selection of papers
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Table 2 Characteristics and assessment of development papers for measures included in the review
PROM Reference(s) Original
language
Construct definition Target population Intended context of use Concept elicitation
study
COSMIN
quality
rating
Were
patients
involved?
BDI Beck et al.
1961 [86]
English
(US)
“the items were chosen on
the basis of their
relationship to the overt
behavioral manifestations of
depression and do not
reflect any theory regarding
the etiology or the
underlying psychological
processes in depression”
Adult patients with
suspected symptoms of
depression
Quantitative assessment
of the intensity of
depression in diagnostic
and research settings
Inadequate No
CALI Palermo
et al. 2004
[87]
English
(US)
“functional impairment,
defined as difficulty in
performing age-appropriate
physical, mental, and social
activities in daily life due to
physical health status (…)
functional impairment due
to pain (…) specific areas of
functioning that are import-
ant to children and adoles-
cents with recurrent and
chronic pain”
School-age children and
adolescents with recurrent
and chronic pain
Research and clinical care Doubtful Yes
DCGM-37 Petersen
et al. 2005
[88]
Ravens-
Sieberer
et al. 2007
[89]
English
(UK)
“a multidimensional
construct with social,
physical, emotional, and
functional domains”
Children aged 4–7 years
and 8–16 years with chronic
health conditions
Clinical studies or surveys Doubtful Yes
EQ-5D-3La EuroQol
Group 1990
[6]
Brooks et al.
1996 [7]
Multiple,
including
English
(UK)
“Health-related quality of
life”
“Large-scale surveys of the
community and (…) for use
in postal surveys”
“Complement other
quality of life measures,
collection of common
data set for reference.
Generate cross-national
comparisons of health
state valuations.”
Inadequate No
FSS Krupp et al.
1989 [90]
English
(US)
“Fatigue” Patients with “clinical
disorders”
Clinical research studies
and surveys
Inadequate No
GAD-7 Spitzer et al.
2006 [91]
English
(US)
“We first selected potential
items for a brief GAD
[Generalized Anxiety
Disorder] scale (…) that
reflected all of the
Diagnostic and Statistical
Manual of Mental Disorders,
Fourth Edition (DSM-IV)
symptom criteria for GAD
and (…) on the basis of
review of existing anxiety
scales.”
General adult population Clinical practice and
research
Inadequate No
HADS Zigmond &
Snaith 1983
[92]
English
(UK)
“depression subscale were
largely based on the
anhedonic state (…)
psychic manifestations of
anxiety neurosis”
Patients under investigation
and treatment in medical
and surgical departments in
non-psychiatric hospital
departments
Clinical/screening use
within non-psychiatric
hospital departments
Inadequate No
HUI-2 /
HUI-3
(15Q)
Feeny et al.
1995 [93]
Torrance
et al. 1996
[94]
English
(US)
“The HUI Mark II and Mark
III systems are based on
concepts of functional
capacity rather than
performance (…) generic
health profile measures that
Originally survivors of
childhood cancer (HUI-2),
extended to adults
Clinical evaluative and
population health survey
studies, in clinical trials,
and cost-utility analyses
Inadequate Unknown
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Table 2 Characteristics and assessment of development papers for measures included in the review (Continued)
PROM Reference(s) Original
language
Construct definition Target population Intended context of use Concept elicitation
study
COSMIN
quality
rating
Were
patients
involved?
also permit the
computation of a single
summary score quantifying
health-related quality of life”
INQoL Vincent
et al. 2007
[95]
English
(UK)
“The structure of INQoL was
based on the ICIDH-2
model of disease
incorporating the concepts
of Impairment, Activities,
and Participation.”
Adults with neuromuscular
disorders (16+ years)
Clinical and research use Inadequate Yes
KIDSCREE
N-52
Ravens-
Sieberer
et al. 2001
[96]
Ravens-
Sieberer
et al. 2005
[97]
Detmar
et al. 2006
[98]
Multiple,
including
English
(UK)
“Health-related quality of
life is described as a
multidimensional construct
covering physical,
emotional, mental, social,
and behavioral components
of well-being and function
as perceived by patients
and/or individuals (…)
agreement was reached
that the questionnaire
should aim to measure
HRQOL as a generic con-
struct in largely healthy chil-
dren, thus more emphasis
was given to the inclusion
of psychosocial domains,
and less to domains of
physical functioning or
symptoms such as pain.”
Healthy and chronically-ill
children and adolescents
between 8 and 18 years
Epidemiological and
paediatric studies, clinical
settings (healthcare
system), and health
services research
Adequate Yes
KIDSCREE
N-27
Ravens-
Sieberer
et al. 2006
[99]
Assumed
the same
as KIDS
CREEN-52
Assumed the same as KIDS
CREEN-52
Assumed the same as KIDS
CREEN-52
Assumed the same as
KIDSCREEN-52
Adequate Yes
KIDSCREE
N-10
Ravens-
Sieberer
et al. 2006
[99]
Assumed
the same
as KIDS
CREEN-52
Assumed the same as KIDS
CREEN-52
Assumed the same as KIDS
CREEN-52
Assumed the same as
KIDSCREEN-52
Adequate Yes
LSIA Reid &
Renwick
1994 [54]
English
(US)
“quality of life is to
conceptualize it as a
subjective phenomenon.
Specifically, it is viewed in
terms of the individual’s
feelings and evaluations of
his or her life
circumstances. Many
researchers who study
quality of life within this
perspective emphasize the
importance of measuring
the individual’s degree of
life satisfaction. In other
words, they are interested
in how pleased an
individual feels about
particular aspects of his or
her life”
“Individuals between the
ages of 12 and 19 years
who have DMD”
Research instrument and
potentially useful as a
clinical measure
Doubtful Yes
MDCHILD Propp, 2017
[100]
Propp et al.
English
(UK)
“Health-related priorities for
children with DMD (…)
defined as concerns,
Children with DMD
(assumed 5–18 years)
Cohort studies, clinical
trials, and clinical decision-
making
Doubtful Yes
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Table 2 Characteristics and assessment of development papers for measures included in the review (Continued)
PROM Reference(s) Original
language
Construct definition Target population Intended context of use Concept elicitation
study
COSMIN
quality
rating
Were
patients
involved?
2019 [8] desires, and expectations
arising from the lived
experience of that
condition”
PedsQL
3.0 DMD
Uzark et al.
2012 [62]
English
(US)
“Health-related quality of
life (QoL), a
multidimensional construct
that includes physical,
psychological, and social
functioning, has emerged
as an important outcome in
pediatric populations with
chronic health conditions.”
Children with DMD from 2
to 18 years
Assumed the same as
PedsQL 4.0 GCS
Doubtful Yes
PedsQL
3.0 MFS
Varni et al.
2002 [101]
English
(US)
“designed to measure child
and parent perceptions of
fatigue in pediatric patients”
Assumed the same as
PedsQL 4.0 GCS
“may be utilized as
outcome measures in
pediatric cancer clinical
trials, research, and clinical
practice for HRQOL”
Inadequate Yes
PedsQL
3.0 NMM
Iannaccone
et al. 2009
[102]
English
(US)
“HRQOL is a
multidimensional construct,
consisting at the minimum
of physical, psychological
(including emotional and
cognitive), and social health
dimensions delineated by
the World Health
Organization. HRQOL has
emerged as the most
appropriate term for quality
of life dimensions that
represent a patient’s
perceptions of the impact
of an illness and its
treatment on their own
functioning and well-being
and which are within the
scope of healthcare services
and medical products.”
Children and young people
with neuromuscular
disorders, in particular
spinal muscular atrophy
Assumed the same as
PedsQL 4.0 GCS
Doubtful Yes
PedsQL
4.0 GCS
Varni et al.
1999 [103]
English
(US)
“The PedsQL measures the
patient’s and the parent’s
perceptions of the patient’s
HRQOL, as defined in terms
of the impact of disease
and treatment on an
individual’s physical,
psychological, and social
functioning, and by
disease/treatment-specific
symptoms.”
Children aged 8–18 across
various pediatric chronic
health conditions
Epidemiological studies,
clinical trials, and
performance
improvement studies
Doubtful Yes
PedsQL
4.0 SF-15
Varni et al.
1999 [103]
English
(US)
Assumed the same as
PedsQL 4.0 GCS
Assumed the same as
PedsQL 4.0 GCS
Assumed the same as
PedsQL 4.0 GCS
Doubtful Yes
PHQ-9 Spitzer et al.
1999 [104]
Kroenke
et al. 2001
[105]
English
(US)
“Depression (…) using
diagnostic criteria from the
Diagnostic and Statistical
Manual of Mental Disorders,
Revised Third Edition (DSM-
III-R) and Diagnostic and
Statistical Manual of Mental
Disorders, Fourth Edition
(DSM-IV).”
General adult population Clinical practice and
research
Inadequate No
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Table 2 Characteristics and assessment of development papers for measures included in the review (Continued)
PROM Reference(s) Original
language
Construct definition Target population Intended context of use Concept elicitation
study
COSMIN
quality
rating
Were
patients
involved?
PODCI Daltroy
et al. 1998
[106]
English
(US)
“The POSNA outcomes
instrument scales assess
upper extremity function,
transfers and mobility,
physical function and
sports, comfort (painfree),
happiness and satisfaction,
and expectations for
treatment. A POSNA global
scale combines the three
function subscales and
comfort.”
Children aged 2–18 years
with musculoskeletal
disorders
“Patient-based instrument” Doubtful Yes
(assumed)
PSQI Buysse et al.
1989 [107]
English
(US)
“sleep quality is a readily
accepted clinical construct,
it represents a complex
phenomenon that is
difficult to define and
measure objectively. ‘Sleep
quality’ includes
quantitative aspects of
sleep, such as sleep
duration, sleep latency, or
number of arousals, as well
as more purely subjective
aspects, such as “depth” or
“restfulness” of sleep”
Clinical/psychiatric
populations
Psychiatric clinical practice
and research activities
Doubtful No
SDQ Goodman
1997 [108]
English
(UK)
“young people’s behaviours,
emotions, and relationships”
Children and young people
(aged 4–16 years)
“to meet the needs of
researchers, clinicians, and
educationalists”
Inadequate No
SF-36
v1.0a
Ware &
Sherbourne
1992 [109]
Hays et al.
1993 [110]
Jenkinson
et al. 1999
[111]
Ware 2000
[112]
English
(US)
““Health”, eight concepts:
physical functioning, social
and role functioning,
mental health, general
health perceptions, bodily
pain, and vitality.”
“General population and
patients”
“Clinical practice and
research, healthy policy
evaluations, and general
population surveys”
Inadequate No
SWLS Diener et al.
1985 [113]
English
(US)
“Life satisfaction refers to a
cognitive, judgmental
process. Shin and Johnson
(1978) define life
satisfaction as “a global
assessment of a person’s
quality of life according to
his chosen criteria” (p. 478)”
Unclear Unclear Inadequate No
WHOQOL-
BREF
WHOQOL
Group 1994
[114]
WHOQOL
Group 1995
[115]
Skevington
et al. 1997
[116]
WHOQOL
Group 1998
[117]
Multiple,
including
English
(UK)
“It is a broad ranging
concept incorporating, in a
complex way, the person’s
physical health,
psychological state, level of
independence, social
relationships, personal
beliefs, and relationship to
salient features of the
environment (…) At
minimum, quality of life
includes the following
dimensions: physical
(individuals’ perception of
“assess the quality of life of
chronic disease sufferers,
informal caregivers of the
sick and disabled, people
living in high-stress condi-
tions like refugees, and
‘healthy’ people”
“in routine clinical work,
large scale
epidemiological studies
and in clinical trials”
Doubtful Yes
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conclusion was rated as very low. Second, the structural
validity of the PedsQL 3.0 NMM in people with DMD
received an unsatisfactory rating, as the psychometric
criteria for good measurement properties were not met.
The favourable risk of bias assessment for Landfeldt
et al. (2018) [66] meant that the quality of evidence sup-
porting this conclusion was graded as high.
Quality assurance of the review
The quality of this review was self-assessed against a
newly derived COSMIN checklist [22], designed to
evaluate the quality of systematic reviews of health-
related PROMs. The results are displayed in
Additional file 3.
In general, the review meets numerous quality in-
dicators as defined by the COSMIN team, including
the elements included in the research aim, search
strategies, article selection, and assessment of meas-
urement properties and quality. In a couple of in-
stances, criteria have been partly met. For example,
in this review all instruments were included where a
validated English copy was freely available for re-
view. It is possible that additional instruments could
have been included if licenses were paid for to ac-
cess the relevant PROMs and development materials,
and this could be considered a limitation. Second,
citation tracking (i.e. reference checking) was con-
ducted on the final set of articles eligible at Stage 2
Table 2 Characteristics and assessment of development papers for measures included in the review (Continued)
PROM Reference(s) Original
language
Construct definition Target population Intended context of use Concept elicitation
study
COSMIN
quality
rating
Were
patients
involved?
their physical state),
psychological (individuals’
perception of their
cognitive and affective
state) and social
(individuals’ perception of
the interpersonal
relationship relationships
and social roles in their life).
(…) The WHOQOL includes
a spiritual dimension (the
person’s perception of
‘meaning in life’, or the
overarching personal beliefs
that structure and qualify
experience).”
aPROM development information from prior COSMIN review [118], not re-extracted or re-rated in this review, based on COSMIN guidance [13]. PROM = patient
reported outcome measure; COSMIN = COnsensus-based Standards for the selection of health Measurement INstruments
Table 3 Characteristics and assessment of content validity papers in DMD samples for measures included in the review
PROM Reference Language
(Country)
DMD sample characteristics COSMIN rating Results (summary)
N Age
(years, ±SD)
%
ambulatory
Relevance Comprehensiveness Comprehensibility
LSIA Simon
et al.
2017 [56]
Brazilian
Portuguese
(Brazil)
43 11.4 ± 3.38 Not stated / Doubtful Doubtful The level of comprehension
reached via the final Probe
technique was 97% for the
parent version and 95% for
the patient version, which is
above the minimum of 85%
required.
PedsQL
3.0
NMM
Hu et al.
2013 [67]
Chinese
(China)
56 7.54 ± 4.06 37 children
“could climb
stairs”
Doubtful Doubtful Doubtful Cognitive debriefing was
conducted with six children
with DMD and their parents
to confirm that the final
Chinese version was
understandable and
acceptable.
/ = content validity aspect not evaluated. PROM = patient reported outcome measure; COSMIN = COnsensus-based Standards for the selection of health
Measurement INstruments
Powell et al. Health and Quality of Life Outcomes          (2020) 18:263 Page 18 of 26
of the searches (n = 41), but not on results eligible
for inclusion at Stage 1.
Discussion
In this systematic review, the published scientific evi-
dence on the content and structural validity of PROMs
used to measure at least one aspect of QoL in people
with DMD was thoroughly evaluated. The overriding
theme was one of sparse evidence. Many PROMs that
are being used to assess aspects of QoL in people with
DMD are being utilised without the accompanying good
quality evidence that supports their validity for this task.
Only five of the PROMs uncovered in this review were
specifically designed for use in people with neuromuscu-
lar problems (three for DMD), and only two of these
have had their content and/or structural validity inde-
pendently assessed in this population (with the content
validity studies involving translated versions). When the
evidence is available, most of it is either of a low quality,
featuring insufficient detail in the published articles to
make thorough and comprehensive assessments of con-
tent and structural validity as demanded by COSMIN
[16], leading to doubtful ratings. Indeed, one of the high-
est quality pieces of evidence reviewed in terms of re-
ported methodology, Landfeldt et al. (2018) [66],
reported insufficient structural validity of the PedsQL
3.0 Neuromuscular module (NMM) in DMD.
The results from the review may not be viewed as sur-
prising. Many of the PROMs identified are what could
be described as “legacy” measures. They were developed
at a time when the science of construct and item gener-
ation was largely overlooked. The content of instruments
was largely defined by clinical or expert opinion, with lit-
tle explanation of what that entailed. The reporting of
Table 4 Evidence synthesis on the content and structural validity of measures that have been used to assess quality of life in
people with DMD
Content validity Structural Validity
PROM Relevance Comprehensiveness Comprehensibility Quality of evidence Rating of results Quality of evidence
BDI ± – ± Very low ? ?
CALI + – ± Low ? ?
DCGM-37 ± + + Low ? ?
EQ-5D-3L + – + Very low ? ?
FSS ± – ± Very low ? ?
GAD-7 + – + Very low ? ?
HADS – – – Very low ? ?
HUI-2 / HUI-3 (15Q) – – – Very low ? ?
INQoL ± ± + Very low ? ?
KIDSCREEN-52 + + + Low ? ?
KIDSCREEN-27 + + + Low ? ?
KIDSCREEN-10 + + + Low ? ?
LSIA + + + Moderate ? ?
MDCHILD ± + + Low ? ?
PedsQL 3.0 DMD ± ? ± Very low ? ?
PedsQL 3.0 MFS ± – ± Very low ? ?
PedsQL 3.0 NMM ± ? ± Moderate – High
PedsQL 4.0 GCS ± + ± Low ? Very low
PedsQL 4.0 SF-15 ± + ± Low ? ?
PHQ-9 + – ± Very low ? ?
PODCI ± + ± Very low ? ?
PSQI ± – ± Very low ? ?
SDQ – – + Very low ? ?
SF-36 v1.0 ± + ± Very low ? ?
SWLS – – ± Very low ? ?
WHOQOL-BREF + + ± Very low ? ?
+ = satisfactory results; − = unsatisfactory results; ± = inconsistent results;? = indeterminate. PROM = patient reported outcome measure
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Table 5 Characteristics, assessment, and results of structural validity papers in DMD samples for measures included in the review
PROM Reference Country
(language)
Patient characteristics COSMIN
Quality
Rating
Analysis –
model
Results (summary)
N Age (yr,
M ± SD)
% ambulatory PROM score
PedsQL
4.0 GCS
Lim et al.
2014 [72]
USA
(English)
63 boys with DMD
(and up to 50 parents,
not necessarily matched)
10.2 ± 2.5 95.24 Child: M = 64.5,
SD = 15.3.
Parent: M =
56.2, SD = 12.9.
Doubtful Rasch (model
not specified)
Model misfit for items determined with infit > 1.4 and
outfit > 2.0 MnSq values and standardized scores > 2.0.
All items fit in parent proxy-reports of physical health
scale and child self-reports of psychosocial health scale.
2 out of 8 items showed high infit statistics in child
self-reports of the physical health scale (taking a bath
or shower; doing chores around the house). In addition
2 out of 15 items showed high infit for the parent
proxy-reports of the psychosocial health scale (trouble
sleeping; keep up with school work).
PedsQL
3.0 NMM
Landfeldt
et al. 2018
[66]
UK / USA
(English)
278 (95 UK) 16 ± 7 40% not “full-time
wheelchair
dependent”
Not reported Very
good
Rasch PCM Eight items displayed inadequate fit (χ2: p > 0.01). Six
items had fit residuals ≤ −2.5 or≥ 2.5 (4 significant
at p < .05). Inadequate overall fit (χ2 item-trait
interaction: p = < .001). Disordered thresholds for
22 of 25 items. Suboptimal targeting.
PROM = patient reported outcome measure; COSMIN = COnsensus-based Standards for the selection of health Measurement INstruments
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such stages in publications or questionnaire manuals
was not commonplace. The transparency of reporting
on the early stages of PROM development has only
gained traction in the last decade or so. Whilst this is a
positive step for researchers, clinicians and users alike,
progress can be limited by journal restrictions on word
count and remit. It is however possible for such legacy
measures to be appropriately validated (or have their val-
idity assessed) in properly designed studies assessing
content or structural validity in modern samples of
people with DMD. The problem observed in this review
is that researchers are likely using such measures as a
consequence of precedent or tradition, rather than a
supportive evidence base.
Another related legacy issue within PROM develop-
ment, which this review touches upon and has changed
for the better over time, is a recognition of the import-
ance of direct patient involvement in developing PROMs
[119, 120]. In this review, almost half (11 out of 26) of
the PROMs did not demonstrate any evidence of patient
involvement in their development. While most of these
PROMs are legacy measures, this is a noteworthy figure,
given that patient involvement is the only way to ensure
a PROM is capturing health and QoL outcomes in a way
that is relevant, comprehensive, and comprehensible to
the patient population [119]. The use of patient involve-
ment in PROM development is thus advantageous for
researchers and patients alike. To help guide PROM de-
velopers, a recent framework has been published to help
researchers fully incorporate patient and public involve-
ment (PPI) in the development of PROMs moving for-
ward [120].
In the current review, some PROMs performed better
than others under COSMIN assessment. First, the KIDS
CREEN instrument (all versions) does show some evi-
dence of applicability given that it covers many aspects
of QoL. The PROM development study for the KIDS
CREEN instrument was the only one rated as adequate,
it was designed to assess QoL in children and adoles-
cents with chronic illnesses, and the ratings for the con-
tent validity of the measure were positive (based on the
available evidence in the measure’s development). How-
ever, it must also be borne in mind that there is little or
no direct evidence to support the content or structural
validity in DMD, specifically. The original KIDSCREEN
instrument (52-item version) was designed to assess
multiple aspects of QoL, namely: physical well-being;
psychological well-being; moods and emotions; self-per-
ception; autonomy; parent relation and home life; fi-
nancial resources; social support and peers; school
environment; and social acceptance (bullying), cover-
ing much of the CMQM framework [9]. The concep-
tual framework of the instrument is thus intuitively
applicable to the Duchenne community; however the
measurement of impact may be limited due to the
target age range of the PROM itself (8–18 years).
While this is not uncommon (i.e. differences in meas-
uring QoL from child to adulthood), there is some
question of the applicability for the broader DMD
population given the lower age target.
The second-best performing PROM in this review was
the LSIA, which received a satisfactory score for rele-
vance, comprehensiveness, and comprehensibility in
terms of content validity, based on the information avail-
able and reviewers’ ratings of the PROM itself. However,
the development study for this paper lacked key details
necessary in good PROM development, and thus was
rated as doubtful. Furthermore, while the LSIA was one
of few measures to feature a content validity study, it
was a cross-cultural adaptation study of a Brazilian ver-
sion of the measure, and the results of the formal assess-
ment of this study were doubtful. While the measure is
comprehensive, it only comes in a 45-item version,
which is potentially quite burdensome. Furthermore, the
measure is designed for use in children and young adults
only, and may not generalise to adults with DMD.
The most recent PROM developed specifically for use
in children and adolescents with DMD was the MDCH
ILD. Although the PROM is designed to measure
“health-related priorities” [8], much of the content maps
onto the CMQM framework [9] and thus covers QoL.
While the MDCHILD had many commendable strengths
in PROM design, the overall rating of the PROM devel-
opment, based on the COSMIN worst score counts sys-
tem [25], was rated as doubtful due to lack of details
reported in the development papers. For example, it was
unclear if skilled interviewer(s) were used; to what de-
gree data was coded independently; and to what degree,
if at all, at least two researchers were involved in the
data analysis. This led to a low quality of evidence. Fur-
ther, because the target population of interest was not
clearly defined (i.e. age ranges were not specified), des-
pite performing well in other areas, the PROM received
an inconsistent rating for relevance. These results speak
to the potential harshness of a worst score counts sys-
tem advocated by COSMIN, which we discuss further
below. Further, because the PROM is new, there is a lack
of published content validity studies that may improve
the quality of evidence for the MDCHILD going for-
ward, such as that contained in a non-peer-reviewed the-
sis [100], not eligible for inclusion in the current review.
The PedsQL and associated modules were the most
commonly used out of all the PROMs identified within
the review. It should be noted that the development
studies of the PedsQL were rated as doubtful. There was
little evidence to support the content validity of the
neuromuscular module of the PedsQL 3.0 (NMM). Fur-
thermore, the psychometric properties of the NMM
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were not well supported by Landfeldt et al. (2018) [66].
The inclusion of PedsQL within clinical practice, cohort
studies or pragmatic trials in DMD thus appears to be
based upon precedent and common use, rather than
published empirical evidence of suitability, based on
content and structural validity. A notable advantage of
the PedsQL (and its derivatives) is the young child (via
proxy report), child (self and proxy report), young adult
forms (self-report), and adult forms, which have now
been developed. A further consideration is that the
PedsQL scales are designed to be used in parallel (e.g.
the generic core scales with the NMM or DMD mod-
ules), but were assessed individually under COSMIN
guidance. Thus comprehensiveness may be improved by
using these scales together.
The search identified some PROM instruments that
we were unable to obtain. Access to the PROM and/or
associated development papers was limited due to li-
censing requirements, and therefore it was not possible
to include these instruments within the review. It is un-
likely that these instruments are commonly used within
research and/or clinical practice due to the difficulties
around access. Their suitability for the DMD population
cannot formally be determined; however, their use is
likely to be limited by a lack of accessibility derived from
license restrictions, reflected in the few citations in
which they appeared.
This review adopted guidance developed by the COS-
MIN initiative, and has adhered to their recommended
methods in identification of evidence, data extraction,
data assessment and data synthesis. Whilst the appropri-
ateness of these robust methods cannot be questioned,
this has resulted in relatively low ratings of the PROMs
included within the review. It is important to recognise
that this does not suggest categorically that the instru-
ments used within published and/or current studies are
not appropriate or fit for purpose; content and structural
validity only form one component of PROM suitability
within a population. Furthermore, as stated, many of the
instruments were developed at a time when instrument
development methods and procedures were not reported
– that is not to say the development of the instruments
is flawed, just that an assessment of them cannot be
made. The COSMIN appraisal tools assume a worst
score counts system for the rating of the methodological
quality of studies [25]. This means that, in theory, a
study could be rated as very good or adequate on all but
one criteria, on which it is rated as doubtful or inad-
equate, and the overall score is thus reduced to the latter
lower-quality rating. Sometimes this can be because key
details, such as whether skilled interviewers were used,
are not reported.
This review is not without its limitations. While the
methodological approach of the review is robust and
follows the recommendations of COSMIN and that of
other published reviews, it must be acknowledged that
the rating criteria of the PROMs identified can be
viewed as harsh. The COSMIN approach encourages re-
searchers and reviewers to critically appraise evidence of
PROM development – however the presence of evidence
within published literature is sparse. That is not to say
that the development phases did not occur, merely that
they are not reported and/or not reported in sufficient
detail as required by COSMIN assessment. To critique a
PROM’s applicability using this criterion could be per-
ceived as being unduly critical; more recent PROMs tend
to report the early stages of instrument development,
and we are assessing all PROMs by modern standards.
Similarly, the descriptions of PROMs themselves are
often lacking. Basic information such as number of
items, recall period, domain structure and scoring pro-
cedure were noted to be sporadically reported, although
better in recent literature. The COSMIN-recommended
reviewer rating of the identified PROMs for suitability
for DMD (as reported in Table 4) has a large subjective
component. Whilst this was completed as per the COS-
MIN guidelines (with two reviewers and discrepancies
reconciled following discussion), some of the ratings are
at risk of bias based on the team of raters (i.e. QoL re-
searchers). For example, it is not known whether similar
ratings of suitability would be achieved if reviewed by an
individual with DMD, a family member or carer of a
person with DMD, or a clinician, and we recommend
that PPI is incorporated in future COSMIN reviews of
content validity. This is further exacerbated when we
consider what QoL is – for the purpose of this review it
was a multidimensional construct, PROMs that measure
a subset of interest (such as depression) may be appro-
priate to include within studies as part of a host/suite of
measures.
The focus of this review was to report on the content
and structural validity of PROM instruments that have
been used to quantify the impact of DMD on individ-
uals’ QoL. However, content and structural validity only
address some aspects of PROM suitability, and further
work could be undertaken to formally appraise the in-
struments described. Other measurement properties,
such as psychometric performance, could be considered.
Given that DMD is a rare condition, the development
and validation of PROMs that measure the impact of the
condition on QoL is challenging. The number of partici-
pants included within various phases of PROM develop-
ment and validation will be lower than that of a
condition such as diabetes, asthma or eczema. Accord-
ingly, the inclusion of subsidiary samples such as other
neuromuscular disorders, may be of interest. However, it
is not known how appropriate this would be. It can be
postulated that other neuromuscular disorders could
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imply similar impacts upon QoL, however this has not
been explored within the context of this review.
Conclusions
In conclusion, evidence on the content and structural
validity of PROMs assessing QoL in DMD is lacking. Ac-
cordingly, our first recommendation from this review is
for more research into the content and structural valid-
ity of QoL PROMs used in DMD, and, if PROMs are
found to be insufficient on these criteria, for additional
PROM development within DMD. Second, as the result
of this COSMIN assessment, without further direct con-
tent validation work in DMD, we would provisionally
recommend the KIDSCREEN for measuring QoL in chil-
dren and adolescents with DMD. Nonetheless, we cau-
tion that the KIDSCREEN has not been formally
validated in samples of people with DMD. Accordingly,
more research is needed to definitively support the con-
tinued use of KIDSCREEN (and its derivatives) within
DMD. Finally, in the absence of further evidence, it is
difficult to recommend the routine use of a measure to
assess QoL in adults with DMD on content and struc-
tural grounds. Instead, the findings of this review sup-
port the need for further PROM development, which is
able to accurately assess the impact of DMD on QoL.
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